Sensei Biotherapeutics (NASDAQ:SNSE) Receives Overweight Rating from Stephens

Sensei Biotherapeutics (NASDAQ:SNSE)‘s stock had its “overweight” rating reissued by research analysts at Stephens in a research note issued on Friday, Benzinga reports. They currently have a $5.00 price objective on the stock.

Sensei Biotherapeutics Stock Down 48.7 %

NASDAQ SNSE traded down $0.71 during trading on Friday, reaching $0.74. 1,166,130 shares of the company’s stock were exchanged, compared to its average volume of 154,953. The company has a 50 day moving average price of $1.22 and a two-hundred day moving average price of $0.92. The company has a debt-to-equity ratio of 0.01, a quick ratio of 12.07 and a current ratio of 12.07. The stock has a market cap of $18.66 million, a P/E ratio of -0.60 and a beta of 0.14. Sensei Biotherapeutics has a 1 year low of $0.51 and a 1 year high of $1.94.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.03). On average, equities research analysts anticipate that Sensei Biotherapeutics will post -1.07 EPS for the current fiscal year.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.